Asthma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmac, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma

The Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, and others

DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]

Some of the key facts of the Asthma Market Report:

*
The asthma market size in the 7MM was around ~USD 19,000 million in 2023, with expectations of growth throughout the forecast period from 2024 to 2034.

*
In February 2025, Enveda, a biotechnology company leveraging AI to transform natural compounds into innovative medicines, is excited to announce the expansion of its lead asset, ENV-294, into a second indication: asthma. Originally developed for atopic dermatitis, this novel therapy offers a groundbreaking approach to treating respiratory inflammatory conditions. To support this progress, Enveda has established an advisory board featuring top experts in asthma research and treatment.

*
In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset's lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD

*
The market size in the 7MM is expected to grow at a compound annual growth rate (CAGR) of approximately 3.9%, driven by rising disease awareness and the introduction of new drugs.

*
In 2023, the UK had the largest market size among EU countries, totaling USD 1.3 million, whereas Spain had the smallest market size at USD 0.4 million.

*
The recent 2024 American Thoracic Society (ATS) conference addressed a wide range of asthma-related topics, from real-world experiences and biomarkers to pediatric asthma and innovative treatments. The conference highlighted significant advancements in asthma research and treatment, including clinical remission indicators and new therapies like inhaled JAK inhibitors and oral STAT6 degraders.

*
The patent protection for the syringe formulation of XOLAIR in the United States and Europe is anticipated to conclude between 2024 and 2025. Currently, there is no presence of generic competition in either the United States or the European Union.

*
CINQAIR possesses biological exclusivity in the United States until 2028 and is granted regulatory exclusivity in Europe until 2026.

*
The collective number of diagnosed prevalent cases of asthma in the 7MM was approximated to be 55 million cases in 2022. Among these cases, the adult population had the highest diagnosed prevalent cases, and this number is anticipated to rise by 2032.

*
As per the World Health Organization (WHO) in 2022, asthma represents a significant non-communicable disease impacting individuals across various age groups, with children being particularly susceptible. It stands as the most prevalent chronic ailment among children. In 2019, approximately 262 million individuals were affected by asthma, resulting in 455,000 deaths.

*
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

*
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

*
The Asthma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market [https://www.delveinsight.com/report-store/asthma-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]

Asthma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Asthma

*
Prevalent Cases of Asthma by severity

*
Gender-specific Prevalence of Asthma

*
Diagnosed Cases of Episodic and Chronic Asthma

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Asthma Therapies and Key Companies

*
GSK3511294 (Depemokimab): GlaxoSmithKline

*
Masitinib (AB07105): AB Science

*
PT010: AstraZeneca

*
Dexpramipexole Dihydrochloride: Areteia Therapeutics

*
ARS 1: ARS Pharmaceuticals, Inc.

*
MEDI3506 (tozorakimab): AstraZeneca

*
AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

*
Atuliflapon (AZD5718): AstraZeneca

*
Amlitelimab: Sanofi

*
Rilzabrutinib: Sanofi

*
BOXABAN (Ifetroban): Cumberland Pharmaceuticals

*
RG6341 (GDC-6599): Genentech Research/Roche

*
CBP-201: Suzhou Connect Biopharmaceuticals

*
AVTX-002 (Quisovalimab): Avalo Therapeutics

*
MRx-4DP0004: 4D Pharma plc

*
SB010: Sterna Biologicals

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]

Asthma Market Strengths

*
Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

Asthma Market Opportunities

*
Availability of varied formulation types and convenient dosing schedules for more effective treatment.

Scope of the Asthma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

*
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

*
Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

*
Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Asthma Unmet Needs, KOL's views, Analyst's views, Asthma Market Access and Reimbursement

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=promotion&utm_campaign=gpr]

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020-2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=asthma-market-to-reach-new-heights-in-growth-by-2034-delveinsight-predicts-glaxosmithkline-ab-science-areteia-therapeutics-ars-pharmac-astrazeneca-pieris-pharma-sanofi-cumberland-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.